ERBB2 and neoplasm: Anti-tumor effects of trastuzumab do not rely on the cell’s dependence on HER2 signaling, and the bystander effects of the T-DXd payload, topoisomerase inhibitor deruxtecan enable targeting rare subpopulations that do not express HER2 (Fig. 6E).